AM-Pharma raises €116m for Phase III
Dutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 243 entries already.
Entries by Uta Mommert
US$5bn deal for Galapagos
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.
Boehringer snaps up cancer vaccine developer
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
€28.5m for microalgae expert Microphyt
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
€8m for universal flu vaccine
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
BioNTech pulls in massive €290m financing
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis launches €9m Nasdaq IPO
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
€30m for Evotec cancer spin-out
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Drug puts CAR T activity on hold
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.